SCHEMBL3430845

SCHEMBL3430845

C#CCN(C)S(=O)(=O)c1ccc(Cn2nc(C(=O)Nc3ccc4c(c3)OCO4)c3ccccc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.45
RAB9A P51151 3/20 0.44
NPSR1 Q6W5P4 3/20 0.44
USP2 O75604 2/20 0.44
TSHR P16473 2/20 0.44
ELANE P08246 1/20 0.44
ATM Q13315 1/20 0.44
ALDH1A1 P00352 5/20 0.44
MAPT P10636 3/20 0.44
NPC1 O15118 2/20 0.43
MEN1 O00255 2/20 0.43
HSD11B1 P28845 1/20 0.42
NPY1R P25929 1/20 0.42
NPY2R P49146 1/20 0.42
HTT P42858 2/20 0.42
GAA P10253 1/20 0.42
KDM4E B2RXH2 1/20 0.41
ESR1 P03372 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3427388 0.90 RAB9A (0.49) KMT2ARAB9ANPSR1USP2TSHR
SCHEMBL3432205 0.86 RAB9A (0.51) KMT2ARAB9ANPSR1USP2TSHR
SCHEMBL3430712 0.85 RAB9A (0.52) KMT2ARAB9ANPSR1USP2TSHR
SCHEMBL13051112 0.84 IDH1 (0.54) KMT2ARAB9ANPSR1USP2TSHR
SCHEMBL3762387 0.84 KDM4E (0.42) KMT2ARAB9AMAPTNPC1MEN1
SCHEMBL3760152 0.84 PTGER4 (0.44) KMT2AALDH1A1MAPTMEN1GAA
SCHEMBL3428179 0.84 RAB9A (0.49) KMT2ARAB9ANPSR1USP2TSHR
SCHEMBL3754165 0.83 ALDH1A1 (0.42) KMT2ARAB9ANPSR1TSHRALDH1A1
SCHEMBL3430664 0.82 RAB9A (0.56) KMT2ARAB9ANPSR1USP2TSHR
SCHEMBL3427905 0.82 MAPT (0.56) KMT2ARAB9ANPSR1USP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP claimed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US claimed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO claimed
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY CPT1B, SMN1; SMN2, GYS1 KMT2A 2516/4885RAB9A 2878/4885NPSR1 2692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.